Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc.

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

Pfizer (NYSE:PFE) has likely turned over all the documents to the Federal Trade Commission regarding its planned $43 billion purchase of cancer-drug maker Seagen (NASDAQ:SGEN). Pfizer (PFE) will ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

The FDA released documents Wednesday giving a look at Pfizer's case for COVID-19 booster shots. The data shows a third dose of Pfizer's shot raised antibody levels with no major safety concerns. An ...

Top drug company marketing executives suppressed a large European study suggesting their blockbuster medication Neurontin was ineffective for chronic nerve pain, and privately strategized about how to ...

CHICAGO (Reuters) - A study of internal company documents suggests Pfizer Inc altered or omitted unfavorable study findings to expand its epilepsy drug Neurontin's market, U.S. researchers said on ...